Masoud Shekarabi
McGill University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Masoud Shekarabi.
Journal of Clinical Investigation | 2008
Masoud Shekarabi; Nathalie Girard; Jean-Baptiste Rivière; Patrick A. Dion; Martin Houle; André Toulouse; Ronald G. Lafrenière; Freya Vercauteren; Pascale Hince; Janet Laganière; Daniel Rochefort; Laurence Faivre; Mark E. Samuels; Guy A. Rouleau
Hereditary sensory and autonomic neuropathy type II (HSANII) is an early-onset autosomal recessive disorder characterized by loss of perception to pain, touch, and heat due to a loss of peripheral sensory nerves. Mutations in hereditary sensory neuropathy type II (HSN2), a single-exon ORF originally identified in affected families in Quebec and Newfoundland, Canada, were found to cause HSANII. We report here that HSN2 is a nervous system-specific exon of the with-no-lysine(K)-1 (WNK1) gene. WNK1 mutations have previously been reported to cause pseudohypoaldosteronism type II but have not been studied in the nervous system. Given the high degree of conservation of WNK1 between mice and humans, we characterized the structure and expression patterns of this isoform in mice. Immunodetections indicated that this Wnk1/Hsn2 isoform was expressed in sensory components of the peripheral nervous system and CNS associated with relaying sensory and nociceptive signals, including satellite cells, Schwann cells, and sensory neurons. We also demonstrate that the novel protein product of Wnk1/Hsn2 was more abundant in sensory neurons than motor neurons. The characteristics of WNK1/HSN2 point to a possible role for this gene in the peripheral sensory perception deficits characterizing HSANII.
Annals of Neurology | 2004
Jean‐Baptiste Rivière; Dominique J. Verlaan; Masoud Shekarabi; Ronald G. Lafrenière; Mélanie Bénard; Vazken M. Der Kaloustian; Zuhayr Shbaklo; Guy A. Rouleau
Hereditary sensory and autonomic neuropathy (HSAN) type II is an autosomal recessive disorder clinically characterized by distal and proximal sensory loss that is caused by the reduction or absence of peripheral sensory nerves. Recently, a novel gene called HSN2 has been found to be the cause of HSAN type II in five families from Newfoundland and Quebec. Screening of this gene in an HSAN type II Lebanese family showed a 1bp deletion mutation found in a homozygous state in all affected individuals. This novel mutation supports the hypothesis that HSN2 is the causative gene for HSAN type II. Ann Neurol 2004;56:572–575
The Journal of Neuroscience | 2012
Masoud Shekarabi; Randal X. Moldrich; Sarah Rasheed; Adèle Salin-Cantegrel; Janet Laganière; Daniel Rochefort; Pascale Hince; Karine Huot; Rébecca Gaudet; Nyoman D. Kurniawan; Susana G. Sotocinal; Jennifer Ritchie; Patrick A. Dion; Jeffrey S. Mogil; Linda J. Richards; Guy A. Rouleau
Disruption of the potassium/chloride cotransporter 3 (KCC3), encoded by the SLC12A6 gene, causes hereditary motor and sensory neuropathy associated with agenesis of the corpus callosum (HMSN/ACC), a neurodevelopmental and neurodegenerative disorder affecting both the peripheral nervous system and CNS. However, the precise role of KCC3 in the maintenance of ion homeostasis in the nervous system and the pathogenic mechanisms leading to HMSN/ACC remain unclear. We established two Slc12a6 Cre/LoxP transgenic mouse lines expressing C-terminal truncated KCC3 in either a neuron-specific or ubiquitous fashion. Our results suggest that neuronal KCC3 expression is crucial for axon volume control. We also demonstrate that the neuropathic features of HMSN/ACC are predominantly due to a neuronal KCC3 deficit, while the auditory impairment is due to loss of non-neuronal KCC3 expression. Furthermore, we demonstrate that KCC3 plays an essential role in inflammatory pain pathways. Finally, we observed hypoplasia of the corpus callosum in both mouse mutants and a marked decrease in axonal tracts serving the auditory cortex in only the general deletion mutant. Together, these results establish KCC3 as an important player in both central and peripheral nervous system maintenance.
Journal of Neurochemistry | 2002
Masoud Shekarabi; Martin Bourbonnière; André Dagenais; Josephine Nalbantoglu
Abstract: Early expression of amyloid precursor protein (APP) during development of the nervous system suggests that this protein may play an important role first in axogenesis and later in synaptogenesis. To study regulation of APP mRNA expression in neuronal cells, NG108‐15 neuroblastoma × glioma cells were induced to differentiate in the presence of dibutyryl cyclic AMP. Steady‐state levels of APP mRNA and APP isoforms increased gradually, concomitantly with the appearance of differentiated phenotype. Northern blot analysis showed a three‐fold increase in APP expression at day 6 of dibutyryl cyclic AMP treatment. Nuclear run‐on assays and transient transfections performed using APP promoter/reporter constructs confirmed a twofold increase in the rate of APP gene transcription. The stability of the mRNA was unchanged, with differentiated and nondifferentiated cells having the same half‐life of about 21 h. These results strongly suggest that APP mRNA induction in the differentiated NG108‐15 cells is due to an increase in the rate of transcription of the gene.
Journal of Biological Chemistry | 2011
Adèle Salin-Cantegrel; Jean-Baptiste Rivière; Masoud Shekarabi; Sarah Rasheed; Sandra Dacal; Janet Laganière; Rébecca Gaudet; Daniel Rochefort; Gaetan Lesca; Claudia Gaspar; Patrick A. Dion; Jean-Yves Lapointe; Guy A. Rouleau
Missense and protein-truncating mutations of the human potassium-chloride co-transporter 3 gene (KCC3) cause hereditary motor and sensory neuropathy with agenesis of the corpus callosum (HMSN/ACC), which is a severe neurodegenerative disease characterized by axonal dysfunction and neurodevelopmental defects. We previously reported that KCC3-truncating mutations disrupt brain-type creatine kinase-dependent activation of the co-transporter through the loss of its last 140 amino acids. Here, we report a novel and more distal HMSN/ACC-truncating mutation (3402C→T; R1134X) that eliminates only the last 17 residues of the protein. This small truncation disrupts the interaction with brain-type creatine kinase in mammalian cells but also affects plasma membrane localization of the mutant transporter. Although it is not truncated, the previously reported HMSN/ACC-causing 619C→T (R207C) missense mutation also leads to KCC3 loss of function in Xenopus oocyte flux assay. Immunodetection in Xenopus oocytes and in mammalian cultured cells revealed a decreased amount of R207C at the plasma membrane, with significant retention of the mutant proteins in the endoplasmic reticulum. In mammalian cells, curcumin partially corrected these mutant protein mislocalizations, with more protein reaching the plasma membrane. These findings suggest that mis-trafficking of mutant protein is an important pathophysiological feature of HMSN/ACC causative KCC3 mutations.
Journal of Neurochemistry | 2002
Martin Bourbonnière; Masoud Shekarabi; Josephine Nalbantoglu
Abstract: The gene for amyloid precursor protein (APP) is expressed almost ubiquitously, with high levels of mRNA being detected in brain. The basal expression level of the APP gene can be modulated by physiological stimuli, and in this report we demonstrate that the second messenger cyclic AMP can regulate APP mRNA through transcriptional mechanisms. Northern blot analysis showed a 1.8‐fold increase in steady‐state levels of APP mRNA when the neuroblastoma × glioma hybrid cell line NG108‐15 was treated with dibutyryl cyclic AMP. Although the upstream sequences of the APP gene do not contain a canonical cyclic AMP response element, transient transfection assays in NG108‐15 cells using different portions of the APP promoter showed an increase in reporter gene activity mediated by sequences located between −303 to −204 and −488 to −2991. Cotransfection assays carried out in HepG2 cells with AP‐2, a cyclic AMP‐regulated transcription factor, failed to activate the APP promoter through the AP‐2 consensus sequence (GCCNNNCGG) located at position −205. Electrophoretic mobility shift analysis revealed that the AP‐2 binding activity present in HeLa nuclear extracts fails to recognize the APP AP‐2 consensus sequence. We conclude that increases in cyclic AMP levels can lead to an up‐regulation of APP gene transcription through at least two different regions of the APP promoter. This increase does not involve the AP‐2 consensus sequence present in the APP promoter located at position −205, and, moreover, this putative site is not recognized by the transcription factor AP‐2.
Modern Pathology | 2016
Roland N Auer; Janet Laganière; Yves Robitaille; John Richardson; Patrick A. Dion; Guy A. Rouleau; Masoud Shekarabi
Hereditary motor and sensory neuropathy associated with agenesis of the corpus callosum (HMSN/ACC) is an autosomal recessive disease of the central and peripheral nervous system that presents as early-onset polyneuropathy. Patients are hypotonic and areflexic from birth, with abnormal facial features and atrophic muscles. Progressive peripheral neuropathy eventually confines them to a wheelchair in the second decade of life, and death occurs by the fourth decade. We here define the neuropathologic features of the disease in autopsy tissues from eight cases. Both developmental and neurodegenerative features were found. Hypoplasia or absence of the major telencephalic commissures and a hypoplasia of corticospinal tracts to half the normal size, were the major neurodevelopmental defects we observed. Despite being a neurodegenerative disease, preservation of brain weight and a conspicuous absence of neuronal or glial cell death were signal features of this disease. Small tumor-like overgrowths of axons, termed axonomas, were found in the central and peripheral nervous system, indicating attempted axonal regeneration. We conclude that the neurodegenerative deficits in HMSN/ACC are primarily caused by an axonopathy superimposed upon abnormal development, affecting peripheral but also central nervous system axons, all ultimately because of a genetic defect in the axonal cotransporter KCC3.
BioTechniques | 1997
Martin Bourbonnière; Masoud Shekarabi; Josephine Nalbantoglu
American Journal of Human Genetics | 2011
Fadi F. Hamdan; Julie Gauthier; Yoichi Araki; Da Ting Lin; Yuhki Yoshizawa; Kyohei Higashi; A. Reum Park; Dan Spiegelman; Amélie Piton; Hideyuki Tomitori; Hussein Daoud; Christine Massicotte; Edouard Henrion; Ousmane Diallo; Masoud Shekarabi; Claude Marineau; Michael Shevell; Bruno Maranda; Grant A. Mitchell; Amélie Nadeau; Guy D'Anjou; Michel Vanasse; Myriam Srour; Ronald G. Lafrenire; Pierre Drapeau; Jean Claude Lacaille; Eunjoon Kim; Jae-Ran Lee; Kazuei Igarashi; Richard L. Huganir
Alpha Omegan | 2011
Fadi F. Hamdan; Julie Gauthier; Yoichi Araki; Da-Ting Lin; Yuhki Yoshizawa; Kyohei Higashi; A-Reum Park; Dan Spiegelman; Amélie Piton; Hideyuki Tomitori; Hussein Daoud; Christine Massicotte; Edouard Henrion; Ousmane Diallo; Masoud Shekarabi; Claude Marineau; Michael Shevell; Bruno Maranda; Grant A. Mitchell; Amélie Nadeau; Guy D'Anjou; Michel Vanasse; Myriam Srour; Ronald G. Lafrenière; Pierre Drapeau; Jean Claude Lacaille; Eunjoon Kim; Jae-Ran Lee; Kazuei Igarashi; Richard L. Huganir